A recent study published in the “Endometriosis and Uterine Disorders” Journal has unveiled promising results regarding CBD-infused tampons for alleviating menstrual pain and severe cramps. The study’s authors posit that these CBD-infused tampons may present a more favorable option with fewer side effects compared to traditional anti-inflammatory medications, offering a parallel pain-relieving impact.
The research team, comprised of six researchers, noted the following in their report: “The outcomes suggest that CBD-infused tampons hold potential as an effective solution for managing menstrual pain.” They emphasized the necessity for further exploration and research into the product, asserting its potential contribution to addressing primary dysmenorrhea, a condition characterized by painful muscle cramps and spasms affecting between 50% and 90% of menstruating women.
The study examined the relationship between CBD, CB2 and CB1 receptors, claiming that because these receptors are extensively dispersed throughout uterine tissue, they provide an ideal target for the localized administration of cannabinoids to reduce pain. A randomized, placebo-controlled methodology was used to conduct the study, and participants were not informed whether they were using a regular or CBD-infused tampon. Participants self-reported their pain thresholds and general levels of satisfaction.
The study group carefully investigated a number of factors, such as systemic toxicity, vaginal irritation, material-mediated pyrogenicity, sensitization, and possible risk of toxic shock syndrome. They confirmed that every test was passed with success, demonstrating the safety of tampons infused with CBD.
Regarding pain alleviation, the report indicated a noteworthy percentage change, reaching 100% in the last menstruation days. Additionally, the study demonstrated a statistically significant decrease in discomfort during particular days of the menstrual cycle, two hours after tampon application.
Although fewer than 5% of participants reported experiencing irritation as a result of using CBD-infused tampons, between 37% and 40% reported an improvement in their vaginal dryness. Two patients reported vertigo while using the product; however, the symptoms cleared promptly without the need for medical treatment after removing the tampon.
The study’s lead author, Valentina Milanova, who also serves as CEO of Daye, a gynecological research company that claims to offer the first CBD-infused tampon worldwide, stated that the observed alleviation of primary dysmenorrhea throughout the menstrual cycle supports the potential effectiveness of CBD-infused tampons. All authors have financial ties to Daye’s parent company, Anne’s Day Ltd., based in London.
The authors did note the study’s shortcomings, particularly its small sample size, and urged future research and improvements to the research design, including the use of a crossover design to collect full pain data.
Cannabis research is still relatively in its infancy, but as the years go by, much more is likely to be known about the health and wellness benefits of the marijuana products currently commercialized by entities such as SNDL Inc. (NASDAQ: SNDL).
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is powered by IBN
